Showing 6551-6560 of 8649 results for "".
- Novartis Confirms 2018 Targets as Alcon Recovery Gains Steamhttps://modernod.com/news/novartis-confirms-2018-targets-as-alcon-recovery-gains-steam/2480224/Swiss drugmaker Novartis’ first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit, according to a
- Allergan Moves in as Shire Rebuffs $63 billion Takeda Bidhttps://modernod.com/news/allergan-moves-in-as-shire-rebuffs-63-billion-takeda-bid/2480225/Drugmaker Shire has rejected a third takeover bid worth nearly $63 billion from Japan’s Takeda Pharmaceutical, although talks are continuing, while sources said Allergan was also in competing
- Nine Members of Congress Honored for Efforts to Preserve Access to Quality Medical Eye Carehttps://modernod.com/news/nine-members-of-congress-honored-for-efforts-to-preserve-access-to-quality-medical-eye-care/2480228/The American Academy of Ophthalmology is honoring nine members of Congress whose legislative efforts are helping to preserve patient access to quality medical and surgical eye care. The Academy is presenting its 2018 Visionary Awards to Sen. Tom Carper, D-Del., Sen. Lisa Murkowski, R-Alaska, Sen.
- Data from BioTime’s OpRegen and Retinal Restoration Programs to Be Presented at ARVO 2018https://modernod.com/news/data-from-biotimes-opregen-and-retinal-restoration-programs-to-be-presented-at-arvo-2018/2480231/BioTime announced that data from the ongoing OpRegen clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29 – May 3, 2018, in Honolulu, Hawaii. The scheduled times (note
- EyePoint Pharmaceuticals’ Yutiq for Posterior Segment Uveitis to be Presented at the 2018 ARVO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-yutiq-for-posterior-segment-uveitis-to-be-presented-at-the-2018-arvo-annual-meeting/2480232/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the Association for Research in Vision and Ophtha
- GlobalData: AI-Based Diabetic Retinopathy Device Can Reduce Burden on US Healthcare Systemhttps://modernod.com/news/globaldata-ai-based-diabetic-retinopathy-device-can-reduce-burden-on-us-healthcare-system/2480234/Iowa-based artificial intelligence (AI) diagnostics company IDx recently received market approval from the FDA for its AI-based medical device, IDx-DR, to detect greater than a mild level of diabetic retinopathy in adults. As the first of its kind to be authorized for commercialization, IDx-DR ha
- American Academy of Optometry 2018 San Antonio Education Program Announcedhttps://modernod.com/news/american-academy-of-optometry-2018-san-antonio-education-program-announced/2480235/The American Academy of Optometry is pleased to announce highlights of the education program taking place at Academy 2018 San Antonio, November 7-10, 2018. The annual meeting offers a wide array of clinically relevant CE courses and cutting-edge research in the clinical and vision sciences. Atten
- Alcon Adds New Gemstone Collection to Air Optix Colors Lens Portfolio and Introduces 2-Count Packshttps://modernod.com/news/alcon-adds-new-gemstone-collection-to-air-optix-colors-lens-portfolio-and-introduces-2-count-packs/2480236/Alcon has introduced its new Air Optix Colors Gemstone Collection of color contact lenses, with three new colors – Amethyst, True Sapphire, and Turquoise. Now offering a total of 12 colors, Air Optix Colors lenses appeal to a wide range of patients and offer a strong incremental revenue potential
- Shire Announces Sale of Oncology Business to Servier for $2.4 Billionhttps://modernod.com/news/shire-announces-sale-of-oncology-business-to-servier-for-2-4-billion/2480237/Shire announced that it has entered into a definitive agreement with privately held French pharmaceutical group Servier S.A.S. to sell its Oncology business for $2.4 billion. “This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio. While the
- Ivantis Announces Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-results-of-comparative-migs-clinical-trial/2480238/Ivantis, developer of the Hydrus Microstent, announced the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study will be presented by David Chang, MD, clinical professor of Ophthalmology at the University of California, San Francisco, during